Equities

Jaguar Health Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Jaguar Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6548
  • Today's Change0.040 / 6.45%
  • Shares traded563.56k
  • 1 Year change-95.40%
  • Beta0.0799
Data delayed at least 15 minutes, as of Mar 04 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

  • Revenue in USD (TTM)11.79m
  • Net income in USD-40.29m
  • Incorporated2013
  • Employees49.00
  • Location
    Jaguar Health Inc200 PINE STREET SUITE 400SAN FRANCISCO 94104United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://jaguar.health/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Panacea Life Sciences Holdings Inc2.76m-7.67m1.73m40.00------0.6255-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.122.58--46.59--12.33------
InVitro International716.89k6.22k1.83m16.00235.002.56--2.550.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
Scisparc Ltd-100.00bn-100.00bn2.09m2.00---------------1.46-----------63.15---90.87-------456.810.5151--1.04---54.64---22.69------
PRF Technologies Ltd0.00-4.09m2.20m2.000.00930.134----301.27301.270.0020.970.00----0.00-57.27-71.03-118.06-84.02------------0.00-------56.12------
LakeShore Biopharma Co Ltd89.13m-14.49m2.47m573.00--0.01720.3710.0277-0.7499-0.74994.653.490.4270.50011.30155,549.80-6.94---15.95--82.47---16.26--0.7452-2.630.453--7.24--76.93------
SOHM Inc-100.00bn-100.00bn2.71m--------------------------------------------------------------
China Pharma Holdings Inc4.05m-3.19m2.76m224.00--0.3322--0.6816-1.10-1.101.281.660.27692.1714.5218,090.54-21.80-18.69-35.67-37.95-10.94-1.14-78.72-44.960.1026-30.500.2884---35.41-16.15-53.84--16.49--
Jaguar Health Inc11.79m-40.29m2.79m49.00--0.7217--0.2368-54.06-54.0612.981.530.21840.20998.78240,510.20-76.04-90.27-152.77-144.3681.9275.33-348.22-458.250.5197-4.620.8759--19.7515.146.80------
60 Degrees Pharmaceuticals Inc1.35m-8.48m3.04m3.00------2.24-23.04-23.042.934.320.19191.592.71451,383.30-113.08---148.26--42.47---589.17--2.63-44.070.0342--168.70---111.48------
Functional Brands Inc6.80m-377.56k3.09m32.00--2.22--0.4551-0.0546-0.05460.96140.08540.88730.352737.24212,408.80-4.93---9.96--91.06---5.55--0.4419-0.87230.6346---3.72--54.93------
CYANOTECH CORP25.27m-1.78m3.18m83.00--0.394116.820.1258-0.2469-0.24693.511.091.052.2112.81304,433.80-7.41-6.08-13.42-8.0532.0032.26-7.03-6.370.2988-1.470.5089--4.96-5.3639.19--1.97--
Bio Essence Corp565.67k-160.45k3.42m2.00------6.05-0.0042-0.00420.0149-0.08161.26--16.06282,835.00-35.64-40.94----69.2838.36-28.36-134.00---57.42-------17.08-286.98------
Data as of Mar 04 2026. Currency figures normalised to Jaguar Health Inc's reporting currency: US Dollar USD

Institutional shareholders

1.75%Per cent of shares held by top holders
HolderShares% Held
Geode Capital Management LLCas of 31 Dec 202524.05k0.64%
DRW Securities LLCas of 31 Dec 202517.82k0.48%
XTX Markets LLCas of 31 Dec 202512.45k0.33%
UBS Securities LLCas of 31 Dec 20256.40k0.17%
Tower Research Capital LLCas of 31 Dec 20253.61k0.10%
RBC Dominion Securities, Inc. (Investment Management)as of 31 Dec 2025702.000.02%
SBI Securities Co., Ltd.as of 31 Dec 2025220.000.01%
Leonteq Securities AGas of 31 Dec 2025188.000.01%
International Assets Investment Management LLCas of 31 Dec 202545.000.00%
Bank of America, NA (Private Banking)as of 31 Dec 202530.000.00%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.